The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
about
Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidenceSystematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori.Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies.Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled TrialAntibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection.Vonoprazan fumarate for the management of acid-related diseases.Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.Treatment of Helicobacter pylori infection 2017.Anti-Helicobacter pylori activity of non-living, heat-killed form of lactobacilli including Lactobacillus johnsonii No.1088.Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey).Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.Single Locoregional Triamcinolone Injection Immediately After Esophageal Endoscopic Submucosal Dissection Prevents Stricture Formation.Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.Survival Benefit of Additional Surgery After Non-curative Endoscopic Submucosal Dissection for Early Gastric Cancer: A Propensity Score Matching Analysis.Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker TestPropensity score-matching analysis to compare clinical outcomes of endoscopic submucosal dissection for early gastric cancer in the postoperative and non-operative stomachs
P2860
Q28072552-FCDE5A54-CDB5-48FB-B499-5EBF96E1C26FQ36369941-F1DB0177-6352-4041-ABB9-C0535C2DF92DQ37393730-CE9E0C02-0240-429C-A217-53D4553F5B0AQ37533456-C98A4A6A-DD33-412E-810A-5280C06931D8Q37699963-CE0B9A9F-F678-4C24-8007-5533F4DE3A14Q38621376-C974F6A6-6C80-4FF3-A4A1-89592DF571B7Q39402205-063D6538-FEFA-4B8F-BFBA-2069B6ECEF55Q39406352-3422F51B-53D7-497B-A16F-5F5F09337878Q40054316-855E5210-364C-4344-8800-484B8420E752Q40212568-4F058EE4-909E-404E-9F0C-286C6C78F899Q40314735-0BF7E0C9-2463-4095-9C6E-2F1D7892F9D2Q40468767-AF8F1B92-8C50-42A5-8A30-1AAF7B2FF57AQ40572311-2BF9EB05-C121-4E7E-9610-1AD48B0FC164Q41771277-5CCB02B6-B441-411A-A526-661AE1A5FAF6Q47225018-2BAA0CA4-EB71-45CD-B567-A48C32F388DEQ47672283-38ED00A6-9717-40B9-9C05-FA6DD12F0D05Q48104849-91C23764-D385-4B8A-AB5D-DD6EE3BBCC53Q48339888-9C0EFDB8-BFAB-44EF-92DC-8862021593D7Q50038775-E04ADE0F-4B45-4244-B30F-F34677CAF76EQ50200654-510AFF5A-E9D7-4BE1-8946-BA1D1A3A4543Q50217765-9DA448CF-ABC3-491C-9671-0C7ADF3813D5Q57819648-A4A2005F-EF9A-428B-90F7-F446B4FEBEFAQ58799394-FE3266A0-68B4-44AB-8C02-2EE7E22A8BCF
P2860
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Efficacy and Tolerability ...... Clarithromycin Triple Therapy.
@en
type
label
The Efficacy and Tolerability ...... Clarithromycin Triple Therapy.
@en
prefLabel
The Efficacy and Tolerability ...... Clarithromycin Triple Therapy.
@en
P2093
P2860
P356
P1476
The Efficacy and Tolerability ...... Clarithromycin Triple Therapy
@en
P2093
Chika Kusano
Kunio Iwatsuka
Mitsuhiko Moriyama
Takuji Gotoda
P2860
P304
P356
10.1038/AJG.2016.182
P407
P50
P577
2016-05-17T00:00:00Z